Scientific breakthroughs can be difficult in a rare disease such as sarcoma, which makes up less than 1% of all adult cancers and comprises more than 50 subtypes.
Treatment with pembrolizumab led to a reduction of tumor size in 33% of patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
When it comes to breast cancer treatments, sometimes less is more, according to Hope S. Rugo, MD.
Patients with chronic phase chronic myeloid leukemia (CML) can safely conclude treatment of tyrosine kinase inhibitors (TKIs) following a maintained deep molecular remission, according to findings from the large EURO-SKI trial presented at the 2016 European Hematology Association (EHA) Congress.
The recent FDA approval of atezolizumab was a significant milestone for the second-line treatment of locally advanced bladder cancer, with even greater potential still on the horizon for the PD-L1 agent.
Bone metastases in castration-resistant prostate cancer create a significant problem. Prostate cancer represents 21% of all new cancer cases in men and is the second most common cause of cancer death among American men after lung cancer.
For patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, the hedgehog/smoothened inhibitors sonidegib and vismodegib have both shown significant benefit.
A recent retrospective analysis of the phase III 80405 trial determined that tumor location played a significant role in survival outcome differences for patients with KRAS wild-type metastatic colorectal cancer (mCRC).
The FDA has approved the cobas HPV Test for use with SurePath Preservative Fluid for the detection of human papilloma virus in cervical cells. SurePath is one of the two approved liquid collection fluids commonly used for Pap tests.
The therapeutic armamentarium for multiple myeloma is ever expanding, according to Sundar Jagannath, MD.
The FDA has released 2 draft guidances regarding the use of next-generation sequencing-based tests.
Given the lack of treatment options for patients with recurrent/metastatic head and neck squamous cell carcinoma, the need for novel therapies is dire.
A variety of dual immunotherapy combination regimens are currently under exploration that could build upon the success seen with the addition of the CTLA-4 inhibitor ipilimumab (Yervoy) to PD-1 blockade with nivolumab (Opdivo) for the treatment of patients with advanced melanoma.
Therapeutic options have been severely limited for patients with locally advanced or unresectable basal cell carcinoma.
An ongoing phase IIa basket study is evaluating treating patients who have molecular abnormalities with agents that target the HER2, BRAF, Hedgehog, or EGFR pathways, regardless of the patient's tumor type and the drug's original indication.
Since its first FDA approval in squamous cell carcinoma of the head and neck (SCCHN) in 2006, cetuximab (Erbitux) has helped oncologists make significant strides in treating patients with the disease.
Patients with advanced renal cell carcinoma who have progressed on cabozantinib (Cabometyx) and nivolumab (Opdivo), now have a promising new treatment option.
Hedgehog inhibitors have revolutionized the treatment paradigm for patients with advanced basal cell carcinoma, says Desiree Ratner, MD.
The role of APRIL/BCMA in multiple myeloma and the targeted agent BION-1301 is discussed by Kenneth Anderson, MD, PhD.
Abiraterone acetate in combination with low-dose prednisone showed a low overall incidence of corticosteroid-associated adverse events that were not significantly different compared with prednisone alone for patients with metastatic castration-resistant prostate cancer.
The high level of efficacy observed with the combination of bortezomib, lenalidomide, and dexamethasone in the phase III SWOG S0777 study significantly changed the frontline treatment paradigm for patients with multiple myeloma.
PD-1/PD-L1 should be the backbone of melanoma treatment for many patients, says Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine.
Despite what many believe, not all radiopharmaceuticals are just for pain palliation, according to Phillip J. Koo, MD.
The combination of the PD-L1 inhibitor durvalumab and the CTLA-4 inhibitor tremelimumab, showed antitumor activity in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), irrespective of PD-L1 status, according to a recent phase Ib study published in The Lancet Oncology.
In an interview with Targeted Oncology, Stacy Loeb, MD discusses how these PSA tests work, what their benefits are, and what urological specialists need to know in order to best utilize them.
With a growing armamentarium for treating metastatic BRAF-mutated melanoma, choosing the right regimen can be difficult, says Jeffrey S. Weber, MD, PhD.
An adjuvant combination of trastuzumab (Herceptin) and paclitaxel could change the treatment paradigm for patients with HER2-positive breast cancer, according to Kimberly L. Blackwell, MD.
Despite limited information on treatment options for mucosal melanoma, Richard Joseph, MD, says immunotherapies could be a rewarding challenge for oncologists to undertake in the field.
With no significant difference between intermittent and continuous androgen-deprivation therapy, patients with prostate cancer may experience an improvement in their quality of life with the former.
While the US Preventive Services Task Force (USPSTF) has issued recommendations against routine PSA-based screening for prostate cancer, E. David Crawford, MD, feels as though this is a step in the wrong direction.